Key Takeaways Sanofi dropped KT-474 but advanced Kymera's IRAK4 degrader KT-485 into clinical development.Gilead signed a $750M deal with Kymera to develop CDK2-targeting molecular glue degraders.KT-621 showed strong phase I results in atopic dermatitis, with phase 2b trials set for 2025-26.It has been a roller coaster ride for Kymera Therapeutics (KYMR) stock this year.  This clinical-stage biotechnology company is pioneering the field of targeted protein degradation (TPD) to develop drugs for various immu ...